text
"['\nX. 대주주 등과의 거래내용\n(1) 당반기 및 전반기 중 회사와 매출 등 거래 또는 채권, 채무 잔액이 있는 특수관계자 현황은 다음과 같습니다.\n관 계\n회 \xa0 \xa0 사 \xa0 \xa0 명\n종속기업\n\xa0㈜유한화학, ㈜유한메디카, ㈜엠지, ㈜유한건강생활, 애드파마㈜, YUHAN UZBEKISTAN, 암호명케이문화산업전문(유), YUHAN USA CORPORATION\n관계기업 및 공동기업\n\xa0유한킴벌리㈜, ㈜유칼릭스, ㈜유한크로락스, ㈜한국얀센, ㈜이뮨온시아, ㈜씨.앤.씨, ㈜워랜텍, ㈜휴이노, ㈜메디오젠, 에스비바이오팜㈜, 메디라마㈜, 에스비바이오팜㈜, \xa0 \xa0 \xa0 ㈜제이인츠바이오, ㈜온코마스터\n기타특수관계자\n\xa0㈜리드팜, 류신(칭다오)건강(유)\n(2) 당반기 및 전반기 중 특수관계자와의 거래 내역은 다음과 같습니다.\n- 당반기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n1,800\n3,600\n-\n-\n-\n-\n-\n-\n46,355,692\n93,126,888\n\xa0㈜유한메디카\n159\n159\n6,900\n13,800\n-\n-\n-\n-\n-\n-\n\xa0㈜엠지\n-\n-\n8,970\n17,940\n-\n-\n-\n-\n4,015,265\n7,300,768\n\xa0㈜유한건강생활\n-\n-\n255,539\n472,707\n-\n30,000\n-\n-\n4,853,958\n8,931,990\n\xa0애드파마㈜\n-\n-\n1,560\n3,120\n-\n-\n-\n-\n3,873,216\n7,306,318\n소 계\n1,959\n3,759\n272,969\n507,567\n-\n30,000\n-\n-\n59,098,131\n116,665,964\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n19,134\n35,765\n\xa0㈜유한크로락스\n1,657\n1,657\n420,040\n719,715\n-\n-\n-\n2,198,000\n19,302,258\n35,783,485\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n97,800,000\n65,556\n201,213\n\xa0㈜한국얀센\n-\n-\n141,316\n307,144\n-\n-\n-\n5,536,450\n9,973,060\n19,793,486\n\xa0㈜이뮨온시아\n-\n-\n20,936\n21,872\n300\n1,200\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,867,670\n3,604,573\n\xa0㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n2,944,268\n3,728,362\n\xa0㈜휴이노\n-\n-\n-\n-\n-\n-\n-\n-\n266,150\n266,150\n\xa0㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n234,570\n1,249,387\n2,650,231\n\xa0에스비바이오팜㈜\n-\n-\n-\n-\n-\n-\n-\n-\n1,915,790\n3,280,587\n\xa0메디라마㈜\n-\n-\n21,987\n29,316\n-\n-\n-\n-\n60,000\n60,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0소 계\n1,657\n1,657\n604,279\n1,078,047\n300\n1,200\n-\n105,809,820\n37,663,273\n69,403,852\n(기타특수관계자)\n\xa0㈜리드팜\n682,127\n1,401,542\n-\n-\n-\n-\n-\n-\n637\n1,923\n\xa0류신(칭다오)건강(유)\n-\n-\n-\n-\n-\n-\n-\n-\n1,158\n1,627\n소 계\n682,127\n1,401,542\n-\n-\n-\n-\n-\n-\n1,795\n3,550\n합 계\n685,743\n1,406,958\n877,248\n1,585,614\n300\n31,200\n-\n105,809,820\n96,763,199\n186,073,366\n- 전반기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n1,800\n-\n-\n-\n-\n-\n-\n31,995,213\n69,335,219\n\xa0㈜유한메디카\n-\n1,455\n6,900\n13,800\n29,878\n29,878\n-\n-\n-\n-\n\xa0㈜엠지\n-\n-\n8,970\n17,940\n-\n-\n-\n-\n3,788,547\n5,336,150\n\xa0㈜유한건강생활\n-\n-\n261,653\n601,304\n5,865\n11,730\n-\n-\n2,967,573\n5,434,508\n\xa0애드파마㈜\n-\n-\n1,560\n31,516\n-\n5,000\n-\n-\n3,715,886\n6,042,659\n소 계\n-\n3,255\n279,083\n664,560\n35,743\n46,608\n-\n-\n42,467,219\n86,148,536\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n15,792\n31,124\n\xa0㈜유한크로락스\n-\n-\n448,283\n788,765\n-\n-\n-\n2,747,500\n18,364,390\n33,421,680\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n19,500,000\n154,020\n705,780\n\xa0㈜한국얀센\n-\n-\n61,627\n181,962\n-\n-\n-\n-\n9,576,184\n18,799,247\n\xa0㈜이뮨온시아\n-\n-\n936\n1,872\n900\n1,800\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,628,787\n3,127,309\n\xa0㈜워랜텍\n-\n-\n-\n-\n26,782\n26,782\n-\n-\n228,811\n422,333\n\xa0㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n234,570\n256,462\n489,462\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0소 계\n-\n-\n510,846\n972,599\n27,682\n28,582\n-\n22,522,870\n30,224,446\n56,996,935\n(기타특수관계자)\n\xa0㈜리드팜\n526,351\n1,269,249\n-\n-\n-\n-\n-\n-\n-\n3,482\n\xa0㈜내츄럴엔도텍\n-\n-\n-\n-\n-\n-\n2\n2\n31,864\n31,864\n소 계\n526,351\n1,269,249\n-\n-\n-\n-\n2\n2\n31,864\n35,346\n합 계\n526,351\n1,272,504\n789,929\n1,637,159\n63,425\n75,190\n2\n22,522,872\n72,723,529\n143,180,817\n(3) 당반기말과 전기말 현재 특수관계자와의 채권ㆍ채무는 다음과 같습니다.\n\xa0(단위:천원)\n특수관계자 명칭\n매출채권\n매입채무\n미수금 등 기타자산\n예수보증금\n당반기말\n전기말\n당반기말\n전기말\n당반기말\n전기말\n당반기말\n전기말\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n-\n11,699,027\n8,340,349\n-\n-\n-\n-\n\xa0㈜유한메디카\n2,530\n-\n-\n-\n-\n-\n400,000\n400,000\n\xa0㈜엠지\n-\n-\n2,649,272\n2,430,683\n2,200,000\n2,200,000\n520,000\n520,000\n\xa0㈜유한건강생활\n90,167\n92,148\n2,349,566\n901,609\n-\n-\n796,800\n796,800\n\xa0애드파마㈜\n-\n-\n18\n1,198,296\n7,581,338\n4,968,729\n-\n-\n소 계\n92,697\n92,148\n16,697,883\n12,870,937\n9,781,338\n7,168,729\n1,716,800\n1,716,800\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n1,265\n132\n-\n-\n-\n-\n\xa0㈜유한크로락스\n462,044\n533,462\n\xa014,957,151\n13,877,347\n-\n-\n-\n-\n\xa0유한킴벌리㈜\n-\n-\n72,112\n88,506\n-\n-\n-\n-\n\xa0㈜한국얀센\n9,266\n-\n3,683,400\n6,591,913\n-\n-\n-\n-\n\xa0㈜이뮨온시아\n22,343\n343\n-\n-\n-\n94,346\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n1,536,464\n1,326,742\n-\n-\n-\n-\n\xa0㈜워랜텍\n-\n-\n2,341,930\n777,538\n-\n-\n-\n-\n\xa0㈜메디오젠\n-\n-\n1,368,092\n5,309,619\n-\n-\n-\n-\n\xa0에스비바이오팜㈜\n-\n-\n923,384\n3,288,226\n-\n-\n-\n-\n\xa0㈜휴이노\n-\n-\n292,765\n-\n-\n-\n-\n-\n\xa0메디라마㈜\n8,062\n-\n-\n-\n-\n-\n42,000\n-\n소 계\n501,715\n533,805\n25,176,563\n31,260,023\n-\n94,346\n42,000\n-\n(기타특수관계자)\n\xa0㈜리드팜\n423,824\n510,481\n-\n-\n-\n-\n-\n-\n\xa0류신(칭다오)건강(유)\n-\n-\n966\n-\n-\n-\n-\n-\n\xa0㈜유앤생명과학\n-\n-\n-\n84,254\n-\n-\n-\n-\n합 계\n1,018,236\n1,136,434\n41,875,412\n44,215,214\n9,781,338\n7,263,075\n1,758,800\n1,716,800\n(4) 당반기 및 전반기 중 특수관계자와의 자금거래 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계 구분\n회사명\n당반기\n전반기\n대여\n회수\n출자\n대여\n회수\n출자\n종속기업\nYUHAN UZBEKISTAN\n-\n-\n20,104\n-\n-\n226,360\n㈜엠지\n-\n-\n907,200\n-\n-\n-\n㈜유한건강생활\n-\n-\n6,900,607\n-\n-\n5,438,142\nYUHAN USA CORPORATION\n-\n-\n7,713,600\n-\n-\n1,666,200\n암호명케이문화산업전문(유)\n-\n-\n2,400,000\n-\n-\n-\n관계기업 및 공동기업\n㈜지아이이노베이션\n-\n-\n-\n-\n-\n9,999,990\n㈜에이프릴바이오\n-\n-\n-\n-\n-\n10,000,066\n㈜아임뉴런바이오사이언스\n-\n-\n-\n-\n-\n2,000,004\n㈜제이인츠바이오\n-\n-\n1,999,997\n-\n-\n-\n㈜온코마스터\n-\n-\n1,999,850\n-\n-\n-\n메디라마㈜\n-\n-\n1,499,971\n-\n-\n-\n㈜테라베스트\n-\n-\n-\n-\n-\n2,999,988\n(5) 당반기말 현재 회사가 특수관계자에게 제공한 지급보증 및 담보 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계자의 명칭\n보증 등의 내용\n금융기관\n보증 금액\n(종속기업)\n㈜유한건강생활\n운전자금대출\n국민은행\n3,850,000\n㈜유한건강생활\n일반대출\n신한은행\n3,600,000\n애드파마㈜\n운전자금대출\n하나은행\n6,000,000\n합 \xa0계\n13,450,000\n(6) 회사는 등기이사 및 회사 기업활동의 계획, 운영 및 통제에 대한 중요한 권한과 책임을 가진 등기 임원을 주요 경영진으로 판단하고 있으며, 당반기 및 전반기 중 주요 경영진에 대한 보상금액은 다음과 같습니다.\n(단위:천원)\n구 \xa0분\n당반기\n전반기\n3개월\n누적\n3개월\n누적\n단기종업원급여\n569,748\n1,139,497\n616,394\n2,111,953\n퇴직급여\n95,798\n191,596\n122,024\n244,048\n합 계\n665,546\n1,331,093\n738,418\n2,356,001\n']"
